SG158158A1 - Glp-1 agonists, compositions, methods and uses - Google Patents
Glp-1 agonists, compositions, methods and usesInfo
- Publication number
- SG158158A1 SG158158A1 SG200908512-7A SG2009085127A SG158158A1 SG 158158 A1 SG158158 A1 SG 158158A1 SG 2009085127 A SG2009085127 A SG 2009085127A SG 158158 A1 SG158158 A1 SG 158158A1
- Authority
- SG
- Singapore
- Prior art keywords
- glp
- methods
- mimetibody
- agonist
- specified portion
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63831304P | 2004-12-22 | 2004-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG158158A1 true SG158158A1 (en) | 2010-01-29 |
Family
ID=37962937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200908512-7A SG158158A1 (en) | 2004-12-22 | 2005-12-22 | Glp-1 agonists, compositions, methods and uses |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070128193A1 (enExample) |
| EP (1) | EP1843788A4 (enExample) |
| JP (1) | JP2008525477A (enExample) |
| KR (1) | KR20070090036A (enExample) |
| CN (1) | CN101415439A (enExample) |
| AU (1) | AU2005337493A1 (enExample) |
| BR (1) | BRPI0519241A2 (enExample) |
| CA (1) | CA2592065A1 (enExample) |
| CR (1) | CR9266A (enExample) |
| EA (1) | EA200701362A1 (enExample) |
| IL (1) | IL183940A0 (enExample) |
| MX (1) | MX2007007602A (enExample) |
| NI (1) | NI200700158A (enExample) |
| NO (1) | NO20073814L (enExample) |
| SG (1) | SG158158A1 (enExample) |
| WO (1) | WO2007046834A2 (enExample) |
| ZA (1) | ZA200706030B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4681231B2 (ja) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | 吸入装置 |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Ｇｌｐ−１分子と制吐剤との医薬製剤 |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| EP1988917A4 (en) * | 2005-12-28 | 2009-08-19 | Zoltan Lab Llc | COMPOSITIONS AND METHODS FOR INCREASING THE VITABILITY AND FUNCTION OF ISLAND CELLS |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| AR064623A1 (es) | 2006-12-21 | 2009-04-15 | Centocor Inc | Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos |
| WO2008092209A1 (en) * | 2007-02-01 | 2008-08-07 | Arana Therapeutics Limited | Protein construct with improved properties |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| MX2011003277A (es) * | 2008-10-14 | 2012-09-21 | Salubrious Pharmaceuticals LLC | Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral. |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| EP2566502A4 (en) | 2010-05-04 | 2013-10-09 | Glaxosmithkline Llc | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION |
| ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| JP2014502984A (ja) * | 2011-01-19 | 2014-02-06 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物 |
| MX353285B (es) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| US9950038B2 (en) * | 2011-08-05 | 2018-04-24 | The Trustees Of The Universiy Of Pennsylvania | Methods and compositions for inhibiting delayed graft function |
| JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| BR112014007124A2 (pt) | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| WO2013128450A1 (en) * | 2012-03-01 | 2013-09-06 | Yeda Research And Development Co. Ltd. | Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| EP3517122A1 (en) | 2013-04-03 | 2019-07-31 | Sanofi | Treatment of diabetes mellitus by long-acting formulations of insulins |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP3289074B1 (en) * | 2015-04-28 | 2023-10-04 | Université de Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
| CN105504026B (zh) * | 2015-12-24 | 2018-12-07 | 广东医科大学 | 一种pac1-r和glp-1r的双向激动剂ot23及应用 |
| US12145993B2 (en) * | 2016-06-08 | 2024-11-19 | Shanghai Jiao Tong University School Of Medicine | Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| KR20230022949A (ko) | 2020-06-03 | 2023-02-16 | 쾨벤하운스 유니버시테트 | Glp1r 작용제 nmdar 길항제 접합체 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| SI1724284T1 (sl) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| US20020187926A1 (en) * | 2001-03-07 | 2002-12-12 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
| US7241733B2 (en) * | 2002-06-28 | 2007-07-10 | Centocor, Inc. | Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses |
| EP1750754A4 (en) * | 2004-03-31 | 2010-09-22 | Centocor Ortho Biotech Inc | HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES |
-
2005
- 2005-12-22 KR KR1020077016979A patent/KR20070090036A/ko not_active Withdrawn
- 2005-12-22 BR BRPI0519241-2A patent/BRPI0519241A2/pt not_active Application Discontinuation
- 2005-12-22 EA EA200701362A patent/EA200701362A1/ru unknown
- 2005-12-22 CN CNA2005800484969A patent/CN101415439A/zh active Pending
- 2005-12-22 AU AU2005337493A patent/AU2005337493A1/en not_active Abandoned
- 2005-12-22 SG SG200908512-7A patent/SG158158A1/en unknown
- 2005-12-22 CA CA002592065A patent/CA2592065A1/en not_active Abandoned
- 2005-12-22 US US11/315,728 patent/US20070128193A1/en not_active Abandoned
- 2005-12-22 JP JP2007548473A patent/JP2008525477A/ja active Pending
- 2005-12-22 WO PCT/US2005/046602 patent/WO2007046834A2/en not_active Ceased
- 2005-12-22 MX MX2007007602A patent/MX2007007602A/es not_active Application Discontinuation
- 2005-12-22 EP EP05858658A patent/EP1843788A4/en not_active Withdrawn
-
2007
- 2007-06-14 IL IL183940A patent/IL183940A0/en unknown
- 2007-06-19 NI NI200700158A patent/NI200700158A/es unknown
- 2007-07-20 ZA ZA200706030A patent/ZA200706030B/xx unknown
- 2007-07-20 CR CR9266A patent/CR9266A/es not_active Application Discontinuation
- 2007-07-20 NO NO20073814A patent/NO20073814L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008525477A (ja) | 2008-07-17 |
| MX2007007602A (es) | 2007-12-07 |
| NI200700158A (es) | 2008-05-13 |
| EA200701362A1 (ru) | 2008-08-29 |
| CR9266A (es) | 2008-09-09 |
| ZA200706030B (en) | 2009-12-30 |
| EP1843788A2 (en) | 2007-10-17 |
| WO2007046834A3 (en) | 2009-06-18 |
| US20070128193A1 (en) | 2007-06-07 |
| WO2007046834A2 (en) | 2007-04-26 |
| BRPI0519241A2 (pt) | 2009-01-06 |
| KR20070090036A (ko) | 2007-09-04 |
| NO20073814L (no) | 2007-09-14 |
| CN101415439A (zh) | 2009-04-22 |
| AU2005337493A1 (en) | 2007-04-26 |
| IL183940A0 (en) | 2007-10-31 |
| EP1843788A4 (en) | 2009-11-18 |
| CA2592065A1 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007007602A (es) | Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. | |
| TW200602491A (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
| WO2008011446A3 (en) | Human glp-1 mimetibodies, compositions, methods and uses | |
| WO2004002417A3 (en) | Mammalian ch1 deleted mimetibodies, compositions, methods and uses | |
| MX2009006892A (es) | Uso de agonistas del receptor de peptido similar al glucagon de tipo 1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles de lipidos. | |
| WO2005081687A3 (en) | Human hinge core mimetibodies, compositions, methods and uses | |
| WO2003084477A3 (en) | Mammalian cdr mimetibodies, compositions, methods and uses | |
| WO2005032460A3 (en) | Human epo mimetic hinge core mimetibodies, compositions, methods and uses | |
| TW200626173A (en) | IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses | |
| WO2005062881A3 (en) | Gene therapy using transposon-based vectors | |
| WO2007005955A3 (en) | Anti-il-23 antibodies, compositions, methods and uses | |
| JO3058B1 (ar) | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها | |
| MX2010004179A (es) | Anticuerpos anti-amiloide, composiciones, metodos y usos. | |
| MA29088B1 (fr) | Composes d'indazole-carboxamide. | |
| TW200716174A (en) | Anti-MCP-1 antibodies, compositions, methods and uses | |
| WO2006124451A3 (en) | Anti-il-13 antibodies, compositions, methods and uses | |
| TW200508246A (en) | Anti-dengue virus antibodies, compositions, methods and uses | |
| AR070143A1 (es) | Gen de bacillus thuringiensis (bt) con actividad contra coleopteros | |
| WO2007035213A3 (en) | Transgenic ungulates expressing ctla4-ig and uses thereof | |
| NO20075272L (no) | Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser | |
| WO2007076319A3 (en) | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses | |
| DK1476012T3 (da) | Transgene mus, der udtrykker PRKAG3 | |
| WO2006039638A3 (en) | Treating renal cell carcinoma with an anti-tnf human antibody or fragment | |
| WO2005067477A3 (en) | Anti-human lymphotoxin alpha antibodies, compositions, methods and uses | |
| WO2008048871A3 (en) | Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses |